The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer

• DOI: 10.4143/crt.2007.39.3.93
• Publication Date: 2009-06-10T03:32:18Z
• Authors: Jae-Sook Ahn; Sang-Hee Cho; Ok-Ki Kim; Joon-Kyoo Lee; Deok-Hwan Yang; Yeo-Kyeoung Kim; Je-Jung Lee; Sang-Chul Lim; Hyeoung-Joon Kim; Woong-Ki Chung; Ik-Joo Chung
• Keywords: Induction chemotherapy; Chemoradiotherapy

Purpose This study was performed to determine the feasibility and safety of use induction chemotherapy combined with docetaxel, cisplatin, 5-fluorouracil (TPF) followed by concurrent chemoradiation therapy for locally advanced squamous cell carcinoma head neck (SCCHN). Materials Methods The patients, that were initially not treated SCCHN, underwent three cycles every 3 weeks at a dose 70 mg/m2 docetaxel D1, 75 cisplatin 1000 5-FU D1-4, subsequently received therapy. Results Forty-nine patients enrolled in this forty-three completed treatment. median duration follow-up 18 months (range, 6~39 months). All had stage III (26.5%) or IV (73.5%) carcinoma. After sequential therapy, complete response partial seen 28 (65.2%) 13 (30.2%) respectively. overall rate 95.4%. Overall survival progression-free (PFS) 2 years 88.7% 69.7%, Grade 3~4 neutropenia occurred 42.2% grade 4 thrombocytopenia 1 cycle (0.7%). Two (4.1%) died during due pneumonia subdural hemorrhage, group over 65 age showed significant lower intensity than under age, but PFS significantly different between two groups (p=0.105). Conclusion TPF chemoradiotherapy high level CR moderate treatment-induced toxicity. Adequate modification elderly should be considered maintain efficacy avoid treatment-related Key words: Head neoplasms, Radiotherapy, Docetaxel, Combination